Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 6, 1999, Pages 653-660

  Schwartz, Jules I ^{a,b,c,d,e,f,g,h,i,j,k}   Chan, Chi Chung ^{a,b,c,d,e,f,g,h,i,j,k}   Mukhopadhyay, Saurabh ^{a,b,c,d,e,f,g,h,i,j,k}   McBride, Kathleen J ^{a,b,c,d,e,f,g,h,i,j,k}   Jones, Terry M ^{a,b,c,d,e,f,g,h,i,j,k}   Adcock, Sherilyn ^{a,b,c,d,e,f,g,h,i,j,k}   Moritz, Carl ^{a,b,c,d,e,f,g,h,i,j,k}   Hedges, Jerris ^{a,b,c,d,e,f,g,h,i,j,k}   Grasing, Kenneth ^{a,b,c,d,e,f,g,h,i,j,k}   Dobratz, David ^{a,b,c,d,e,f,g,h,i,j,k}   Cohen, Robert A ^{a,b,c,d,e,f,g,h,i,j,k}   Davidson, Michael H ^{a,b,c,d,e,f,g,h,i,j,k}   Bachmann, Kenneth A ^{a,b,c,d,e,f,g,h,i,j,k}   Gertz, Barry J ^{a,b,c,d,e,f,g,h,i,j,k}  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Frosst Center for Therapeutic Research   (United States)

^c J and S Studies   (United States)

^d HealthQuest Research   (United States)

^e Alpine Research Optics   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h IMTCI   (United States)

ⁱ Novum Inc   (United States)

^j RADIANT RESEARCH   (United States)

^k UNIVERSITY OF TOLEDO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC ANALGESIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; LIPOPOLYSACCHARIDE; ROFECOXIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPYRETIC ACTIVITY; ARTICLE; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BODY TEMPERATURE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEVER; IBUPROFEN; ISOENZYMES; LACTONES; LIPOPOLYSACCHARIDES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SAIMIRI; SULFONES; TREATMENT OUTCOME;

EID: 0033051086     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)90087-5     Document Type: Article

References (36)

1. 1. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med 1991; 324:1716-25.
2. 2. Insel PA. Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, editors. Goodman and Gilmans the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990. p. 638-81.
3. 3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 1971;231:232-5.
4. 4. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
5. 5. Stitt JT. Prostaglandin E as the neural mediator of the febrile response. Yale J Biol Med 1986;59:137-49.
6. 6. Crofford LJ, Wilder RL, Ristimaki AP. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest 1994;93:1095-101.
7. 7. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991;1083:121-34.
8. 8. Goppelt-Struebe M. Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression. Prostaglandins Leukot Essent Fatty Acids 1995;52:213-22.
9. 9. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-8.
10. 10. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthetase in cultured epithelial cells. J Biol Chem 1992;267:21438-45.
11. 11. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996;62:167-215.
12. 12. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthetase in rat pre-ovulatory follicles: induction in vivo and in vitro. J Biol Chem 1992;267:11586-92.
13. 13. Lee SH, Soyoola E, Chanmugan P, Hart S, Sun W, Zhong H, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-8.
14. 14. Akarasereenont P, Mitchell JA, Appleton I, Thiemermann C, Vane JR. Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol 1994;113:1522-8.
15. 15. Lyons-Giordano BL, Pratta MA, Galbraith W, Davis GL, Arner EC. Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. Exp Cell Res 1993;206:58-62.
16. 16. Cao C, Matsumura K, Yamagata K, Watanabe Y. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res 1995;697:187-96.
17. 17. Cao C, Matsumura K, Yamagata K, Watanabe Y. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever. Brain Res 1996;733:263-72.
18. 18. Cao C, Matsumura K, Yamagata K, Watanabe Y. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. Am J Physiol 1997;272:R1712-25.
19. 19. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-7.
20. 20. Chan, CC, Panneton M, Taylor AM, Therien M, Rodger IW. A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. Eur J Pharmacol 1997;327:221-5.
21. 21. Kurokawa M, Imakita M, Kumeda CA, Shiraki K. Cascade of fever production in mice infected with influenza virus. J Med Virol 1996;50:152-8.
22. 22. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47.
23. 23. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
24. 24. American Society for Testing and Materials. Standard specifications for electronic thermometers for intermittent determination of patient temperature (E1112-86). Annual book of ASTM standards; vol 14.03. Temperature measurement. West Conshohocken (PA) 1996. p. 396-9.
25. 25. Ehrich EW, Schnitzer T, McIlwain H, Levy R, Wolfe F, Weisman M, et al. MK-966, a highly selective COX-2 inhibitor, is effective in the treatment of osteoarthritis in a 6-week pilot study. Osteoarthritis Cartilage 1997(suppl A);5:66.
26. 26. Blatteis CM. Role of the OVLT in the febrile response to circulating pyrogens. Prog Brain Res 1992;91:409-12.
27. 27. Coceani F, Lees J, Bishai I. Further evidence implicating prostaglandin E2 in the genesis of pyrogen fever. Am J Physiol 1988;254:R463-9.
28. 28. Dinarello CA. Thermoregulation and the pathogenesis of fever. Infect Dis Clin North Am 1996;10:433-49.
29. 29. Saper CB, Breder CD. Endogenous pyrogens in the CNS: role in the febrile response. Prog Brain Res 1992;93:419-29.
30. 3. Nature 1998;395:281-4.
31. 31. Cranston WI, Luff RH, Rawlins MD, Rosendorff CJ. The effect of salicylate on temperature regulation in the rabbit. J Physiol 1970;208:251-9.
32. 32. Alder RD, Rawlins M, Rosendorff C, Cranston WI. The effect of salicylate on pyrogen-induced fever in man. Clin Sci 1969;37:91-7.
33. 33. Vargas R, Maneatis T, Bynum L, Peterson MS, McMahon FG. Evaluation of the antipyretic effect of ketorolac, acetaminophen, and placebo in endotoxin-induced fever. J Clin Pharmacol 1994;34:848-53.
34. 34. Simila S, Kouvalainen K, Keinanen S. Oral antipyretic therapy: evaluation of ibuprofen. Scand J Rheumatol 1976;5:81-3.
35. 35. Kauffman RE, Sawyer LA, Scheinbaum ML. Antipyretic efficacy of ibuprofen vs acetaminophen. Am J Dis Child 1992;146:622-5.
36. 36. Motrin (ibuprofen). In: Physician's desk reference. Montvale (NJ): Medical Economics; 1997. p. 1563-5.